SCHEMBL2413442

SCHEMBL2413442

CC(C)(Sc1nc(CC(=O)Nc2ccc(-c3ccc(Cl)cc3)cc2)cs1)C(=O)O

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CTPS1 P17812 5/20 0.48
▸ MAPT P10636 5/20 0.46
▸ LMNA P02545 3/20 0.46
▸ HTT P42858 2/20 0.44
▸ ALDH1A1 P00352 1/20 0.44
▸ TSHR P16473 1/20 0.44
▸ MEN1 O00255 3/20 0.43
▸ KMT2A Q03164 3/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ TP53 P04637 1/20 0.43
▸ GAA P10253 1/20 0.43
▸ SHMT1 P34896 2/20 0.43
▸ SHMT2 P34897 1/20 0.42
▸ PPARA Q07869 2/20 0.42
▸ CYP1A2 P05177 1/20 0.41
▸ CYP3A4 P08684 1/20 0.41
▸ CYP2D6 P10635 1/20 0.41
▸ CYP2C9 P11712 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2413792 0.90 CTPS1 (0.48) CTPS1MAPTLMNAHTTALDH1A1
SCHEMBL2416071 0.88 LMNA (0.60) CTPS1MAPTLMNAHTTMEN1
SCHEMBL2409605 0.87 MEN1 (0.57) CTPS1MAPTLMNAHTTALDH1A1
SCHEMBL2412445 0.86 SMN1; SMN2 (0.48) CTPS1MAPTLMNAHTTALDH1A1
SCHEMBL2415598 0.80 POLB (0.51) MAPTLMNAHTTALDH1A1SMN1; SMN2
SCHEMBL2416827 0.80 TP53 (0.50) MAPTLMNAHTTALDH1A1MEN1
SCHEMBL2411182 0.78 PPARA (0.42) LMNAALDH1A1SMN1; SMN2TP53PPARA
SCHEMBL2412833 0.77 MAPT (0.46) CTPS1MAPTLMNAHTTTSHR
SCHEMBL2410536 0.77 PPARA (0.43) MAPTLMNASMN1; SMN2TP53PPARA
SCHEMBL5561572 0.77 MAPT (0.54) MAPTALDH1A1MEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8026370-B2 Peroxisome proliferator antagonist; hyperlipemia agents; arteriosclerosis; antiischemic agents MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-09-27 — — US claimed
US-8026370-B2 Peroxisome proliferator antagonist; hyperlipemia agents; arteriosclerosis; antiischemic agents MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-09-27 — — US disclosed
US-20080167307-A1 Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof MITSUBISHI PHAMA CORPORATION (JP) 2008-07-10 — — US disclosed
EP-1816128-A1 CARBOXYLIC ACID DERIVATIVE CONTAINING THIAZOLE RING AND PHARMACEUTICAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2007-08-08 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167307-A1 Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof PPARA, PPARD, PPARG CTPS1 359/4885MAPT 3435/4885LMNA 3376/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback